long term side effects of glp-1 receptor agonists Do drugs cause cancer? New review says no, may even protect GLP-1 Agonists and Orthopedic Surgery:

The post describes tirzepatide as a dual GLP-1 and GIP receptor agonist that increases insulin sensitivity, slows gastric emptying and reduces appetite, while the lipotropic components are aimed separately at fat mobilization

For best results, combine with diet and exercise

Systematic meta-analyses have established that sulfonylurea therapy shows no protective effect against prostate cancer development in patients with diabetes mellitus [102]

As we age, our natural peptide production declines, which is why targeted peptide therapy has become one of the most exciting tools in functional and integrative medicine

By Michael Jurgelewicz, DC, DACBN, DCBCN, CNS

Track bonus progress and stop if the math no longer fits your goals